Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 3/20 | 0.36 |
| ▸ | RARB | P10826 | 2/20 | 0.36 |
| ▸ | RXRB | P28702 | 2/20 | 0.36 |
| ▸ | RXRG | P48443 | 2/20 | 0.36 |
| ▸ | RARA | P10276 | 2/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9985591 | 0.81 | HTR7 (0.36) | HTR7NQO2MTNR1AMTNR1BRXRA | |
| SCHEMBL31121639 | 0.78 | HTR6 (0.56) | HTR7HTR6NQO2MTNR1AMTNR1B | |
| SCHEMBL2338975 | 0.78 | HTR6 (0.56) | HTR7HTR6NQO2MTNR1AMTNR1B | |
| SCHEMBL3874874 | 0.74 | HTR6 (0.53) | HTR7HTR6NQO2MTNR1AMTNR1B | |
| SCHEMBL28220073 | 0.73 | HTR6 (0.53) | HTR6SIGMAR1 | |
| SCHEMBL8158082 | 0.72 | RARB (0.40) | RXRARARBRXRBRXRGRARA | |
| SCHEMBL5859128 | 0.71 | HTR6 (0.50) | HTR7HTR6NQO2MTNR1AMTNR1B | |
| SCHEMBL12043859 | 0.71 | NQO2 (0.36) | HTR7NQO2MTNR1AMTNR1B | |
| SCHEMBL3868123 | 0.70 | HTR6 (0.53) | HTR7HTR6NQO2MTNR1AMTNR1B | |
| SCHEMBL6909595 | 0.69 | RXRA (0.61) | RXRARARBRXRBRXRGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383848-B2 | Transition metal compound and catalyst for olefin polymerization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110319578-A1 | TRANSITION METAL COMPOUND AND CATALYST FOR OLEFIN POLYMERIZATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319578-A1 | TRANSITION METAL COMPOUND AND CATALYST FOR OLEFIN POLYMERIZATION | AP1M1, SOD1, YAP1 | HTR7 4438/4885HTR6 4382/4885NQO2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.